Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

• Status: Completed
• Trial end date: 2020-06-24
• Target enrollment: 0
• Participant gender: All

Summary

A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia care unit. Current and maximum intensity pain scores will be documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24 hours will be collected from the EHR and pain diary after discharge. Patient satisfaction will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing notes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Los Angeles
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Patients undergoing laparoscopic donor nephrectomy

Exclusion Criteria:

• Pregnancy

• Systemic or local infection at the potential block site.

• Allergy or hypersensitivity to the local anesthetic,

• Possible variations in surgical approach to donor nephrectomy other than what is defined in this protocol.

• Scarring or anatomic abnormality over the proposed injection site